STING1 and neoplasm: These results suggest (i) there is baseline negative immune checkpoint regulation in this model that can be therapeutically targeted using combination ICI therapy, but not monotherapy and (ii) STING activation results in further upregulation of negative T cell co-stimulatory pathways that can be targeted to improve tumor clearance.